Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05p -1.71% 2.875p 5,104,207 09:09:12
Bid Price Offer Price High Price Low Price Open Price
2.80p 2.95p 3.375p 2.85p 3.15p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.5 -0.3 -0.1 - 8.10

Feedback (FDBK) Latest News (2)

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:09:422.9533,562990.08O
08:08:072.9020,763602.13O
08:08:042.90103,4482,999.99O
08:06:202.9014,000406.00O
08:05:112.9575,0002,212.50O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
27/4/2018
09:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 2.93p.
Feedback Plc has a 4 week average price of 1.20p and a 12 week average price of 1.20p.
The 1 year high share price is 4.13p while the 1 year low share price is currently 1.20p.
There are currently 281,616,584 shares in issue and the average daily traded volume is 14,519,357 shares. The market capitalisation of Feedback Plc is £8,659,709.96.
25/4/2018
11:12
lr2: Hi Chopper, always nice to take a profit but I'm hanging on. This is going to be a really big one I reckon and the share price still doesn't reflect the future profit stream to me. I will be here for some time yet. Don't go away too long.
16/4/2018
14:15
lr2: Apparently the daffodils are in 'full bloom' at TexRAD HQ. Share price in 'full bloom' next I hope. https://twitter.com/search?q=%23texrad&src=typed_query
21/3/2018
09:57
lr2: Hi Duc, Nothing new in the podcast but very upbeat nevertheless. The two guys doing all the talking roughly said the following. TexRAD "hugely successful around the globe". Software spots conditions invisible to naked eye. Cadran - medical images archiving - in venture with Future Processing of Poland. Spinoff Stone Checker - royalties will come to Feedback. Investors perplexed by share price performance. Since CE Mark for TexRAD Lung price has declined from 5p. Reason - Trevor Brown selling down (see previous post #1390 for latest detail). Said TB likes new CEO David Crabb but believes board has too many members and none have skin in the game. With business at turning point DC & LM are likely to become significant shareholders in near future. The guys believe Feedback offers significant value and that there isn't a better time to buy in. Hope that helps. LR2.
19/3/2018
18:54
ducatiman: He would be selling at a loss at these levels surely? It is obvious that he just wants to damage the company and its share price or he has an urgent need for cash!
27/2/2018
17:54
lr2: Revenue for the half year was £229k but expectation for 2nd half of year is better so perhaps they will manage £500k+ for full year. Not enough to go without more financing but perhaps not a placing with the share price so weak. Some form of short term bank financing might be considered if share price remains weak and clinical sales come in soon. Whilst a placing is always likely it is not the only option. Probably won't have long to wait to find out the answer as to which way they will go.
20/12/2017
12:58
lr2: What's likely happening here is a petulant old man with a very large holding is pished off with the board of directors now he is no longer a part of it. To hurt the company he used to be an integral part of, he has decided to sell vast numbers of his shares into the market rather than arrange an orderly market disposal, The result - a forcing down of the share price from 3.75p when he started selling to today's opening 1.6p. Even though he is losing vast amounts of money on his remaining holding he views that as worthwhile to his cause. If anyone has an alternative viewpoint on the man's sales then I'd be happy to hear it espoused here.
20/12/2017
11:58
lr2: If TB continues at his current rate of selling 7 million shares a month, he will be done by mid April. What puzzles me is the effect his sales have had on his remaining holding and why he is apparently happy to let it continue. When he first started selling around 6 months back the share price was 3.75p - 4p. It is now 1.6p - 1.62p. In effect TB has reduced the value of his remaining 30.9 million shares by 2.15p a share thus lowering the value of the remaining shares by almost £665k. Why he persists in this self destructive behaviour one can only surmise for he could have arranged an orderly market disposal had he wished but he chose not to do so. I can only conclude his actions are a symbol of his petulance at the current board of directors for some perceived slight.
11/12/2017
16:45
ydderf: Bear Case: The problem here is that there is unlikely to be any news of revenue over the next few months (unless you include research sales), and even if there are more CE applications approved that doesn't equate to revenue. Fact is the technology has been around for nearly three years in an AIM vehicle, the market cap of which has frequently been below £2m, and so by implication any potential acquirer has had lots of time to run the slide rule over it and consider an offer........Meanwhile the cash figures we have relate to 31st May. Undoubtedly they are lower now and revenue does not match expenses. As the months pass the probability of a further fund raise and dilution will come into focus. As far as I can see there are no constraints on the Board to issue more paper, they have hardly any skin in the game. Bull Case: The good news is that the success of this as an investment is not dependent on the 'caretaker' Board. A sales volcano may erupt beneath their feet but if so it will not have been of their doing. In addition to the in-house CE marked projects with e.g. Alliance, many research versions are now being used throughout the world to trial specific applications any one of which could result in a major diagnostic and commercial breakthrough. A typical project runs for two years plus, so any one of the research versions sold over two years ago could produce a result which nobody is anticipating. There is now a pipeline of such projects underway One modest commercial contract won would be a Richter event in relation to the puny market cap. As such, the share-price at this level is just option money
08/12/2017
13:16
curlly: good to see the share price going up.
22/11/2017
14:20
mikealig: A lot of shares but only worth around £750K at the current share price. As I mentioned before, the real key is whether the company is able to seriously monetise their technology. If they can, then this overhang could disappear in a flash. I'm not well enough informed to know what the potential clients would pay to license this technology. It sounds great but could anyone here put a figure on it?
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180427 08:25:06